Outpatient pharmaceutical agents and classes submitted under the medical benefit require prior authorization (X) as listed. Examples of agent classes with example products: aflibercept (Eylea and biosimilars), alpha‑1 proteinase inhibitors (Aralast NP, Glassia, Prolastin‑C, Zemaira), bortezomib (Velcade), corticosteroid ophthalmic injections (Dextenza, Iluvien, Ozurdex, Yutiq), denosumab (Prolia, Xgeva), eculizumab (Soliris), exon‑skipping therapies (Exondys‑51, Amondys‑45, Viltepso, Vyondys‑53), gene therapies/CAR‑T (multiple named products), GnRH agonists (Lupron Depot, others — note: Camcevi no PA for urology/hematology/oncology), HAE agents, immune globulins (IVIG examples; Preferred: Gammagard, Gamunex‑C), IV iron (Injectafer, Monoferric), lysosomal storage disorder therapies, natalizumab, omalizumab, PD‑1/PD‑L1 inhibitors, pemetrexed, PAH agents, ranibizumab, tocilizumab, ustekinumab (preferred products listed), viscosupplementation (preferred products listed), and many named brand products enumerated in the outpatient pharmaceuticals list.
For the reference product, all generics or biosimilar drugs will require a prior authorization; biosimilars are required in lieu of branded drugs and require prior authorization. Preferred biosimilars are required in lieu of branded drugs and members must try preferred products prior to non‑preferred approval.
Some specialty exceptions noted: e.g., bevacizumab agents (Avastin and biosimilars) — no PA required for ophthalmologists; certain rituximab and ESA/filgrastim products have specified PA exceptions when administered under the medical benefit or for specific specialties.